Articles

A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Read More ›

Financial toxicity can have a negative effect on outcomes for patients with cancer. However, findings from a recent pilot study revealed that a comprehensive intervention focused on the financial aspects of care significantly improved quality of life for patients with hematologic malignancies. Read More ›

Approximately two-thirds of patients with chronic-phase chronic myeloid leukemia (CML) achieved a major cytogenetic response to the novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they had received previous treatment with ponatinib (Iclusig), according to findings from a recent phase 1 clinical trial. Read More ›

In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion. Read More ›

Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in applying the use of targeted therapies in the treatment of patients with cholangiocarcinoma (CCA). Read More ›

Prior to the COVID-19 pandemic, nurses were already facing a high burnout rate—with nearly 4 out of 10 nurses reporting they felt burned out—possibly due to long hours, increased workloads, weak work cultures, fragmented communication from leadership, and the emotional toll from caring for significantly ill patients. Read More ›

This section provides a brief overview of new cancer drugs or new indications approved by the FDA between December 16, 2020, and January 14, 2021. Read More ›

IKEMA is an ongoing, phase 3, randomized, open-label, parallel-group study that reached its interim analysis milestone. The study evaluated the effect of adding isatuximab (Isa) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM) at target dose levels of ≥150 × 10⁶ chimeric antigen receptor (CAR)+ T-cells, the updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, idecabtagene vicleucel. Read More ›